Andres Izquierdo has notable professional experience on consumer issues/safety/products, copyright, patent & trademark, healthcare, medicare & medicaid, and pharmaceuticals issues. Andres previously worked full-time for AstraZeneca Pharmaceuticals LP.

Areas of Experience

ASTRAZENECA PHARMACEUTICALS LP
Duration : 2.2 years (2007 - 2009) inactive
Revenue : $400,000.00 (monthly) - $12,960,000.00 (total)
- Discussions regarding protection of patient safety from the commercial importation of prescription medications Discussions regarding impact and safety issues surrounding the presence of pharmaceuticals in the environment - No specific legislation HR 5839-The Safeguarding America's Pharmaceuticals Act-US House Import Safety Discussion Draft legislation-US House/US Senate
ASTRAZENECA PHARMACEUTICALS LP
Duration : 2.2 years (2007 - 2009) inactive
Revenue : $400,000.00 (monthly) - $12,960,000.00 (total)
- Patent Reform and intellectual property issues Section 182 ("Special 301") briefings on global intellectual property protections Discussions regarding patent settlements (reverse payments) legislation Discussions regarding follow on biologics
ASTRAZENECA PHARMACEUTICALS LP
Duration : 2.2 years (2007 - 2009) inactive
Revenue : $400,000.00 (monthly) - $12,960,000.00 (total)
- H.R. 1424 The Paul Wellstone Mental Health and Addiction Equity Act of 2007 S. 1893-Children's Health Insurance Program Reauthorization Act H.R. 3162-Children's Health Insurance Program Reauthorization Act S.558-The Mental Health Parity Act of 2007 S. 1376 - 340B Program Improvement and Integrity Act of 2007
ASTRAZENECA PHARMACEUTICALS LP
Duration : 2.2 years (2007 - 2009) inactive
Revenue : $400,000.00 (monthly) - $12,960,000.00 (total)
- Medcaid Base Rebate Increase-US House Medicare:S.3101/H.R. 6331-The Medicare Improvements for Patients & Providers Act S.3118-The Preserving Access to Medicare Act Waxman proposal for Medicaid-type rebates for dual elibigles enrolled in Medicare Part D. No active legislation-US House Discussions regarding maintenance of six protected classes of pharmaceutical products under Medicare Part D Anti-Preemption Medicare Part D-US House
ASTRAZENECA PHARMACEUTICALS LP
Duration : 2.2 years (2007 - 2009) inactive
Revenue : $400,000.00 (monthly) - $12,960,000.00 (total)
- Discussions regarding FDA Appropriations Discussions regarding e-Prescribing Discussions regarding implementation of PDUFA IV/FDAAA Direct-to-Consumer Advertisement User Fee Program

TAX

ASTRAZENECA PHARMACEUTICALS LP
Duration : 2.2 years (2007 - 2009) inactive
Revenue : $400,000.00 (monthly) - $12,960,000.00 (total)
- Renewal of Research and Development Tax Credit within context of proposed changes to Alternative Minimum Tax
ASTRAZENECA PHARMACEUTICALS LP
Duration : 2.2 years (2007 - 2009) inactive
Revenue : $400,000.00 (monthly) - $12,960,000.00 (total)
- International trade issues, including free-trade agreements Import Safety
ASTRAZENECA PHARMACEUTICALS LP
Duration : 2.2 years (2007 - 2009) inactive
Revenue : $400,000.00 (monthly) - $12,960,000.00 (total)
- S.5 & H.R. 3 - Stem Cell Research Enhancement Act of 2007

Top Expertise

  • CONSUMER ISSUES/SAFETY/PRODUCTS
  • COPYRIGHT
  • PATENT & TRADEMARK
  • HEALTHCARE
  • MEDICARE & MEDICAID
  • PHARMACEUTICALS

Employers

Current

Past

  • ASTRAZENECA PHARMACEUTICALS LP